Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2025 Oct 31;11(11):3050–3060. doi: 10.1021/acsinfecdis.5c00260

Development of a Promising Ferritin-Based Bioconjugate Nanovaccine Candidate against Brucellosis

Wenjun Li †,‡, Juntao Li ‡, Xueping Cao †,§, Na Song §, Ting Li ‡, Jingqin Ye ‡, Ziyuan Chen ‡, Yufei Lyu ‡, Li Zhu ‡, Zhaoyang Liu §, Xiaoli Yang †,§, Hengliang Wang ‡, Chao Pan ‡,*, Yufei Wang †,§,*
PMCID: PMC12626113  PMID: 41171198

Abstract

Brucellosis, a global zoonosis caused by Brucella species, currently lacks safe vaccines for human use, while existing veterinary live-attenuated vaccines pose infection risks. Although ferritin nanoparticle materials have shown significant advantages in delivery, there is not much research on loading complex polysaccharide antigens. Here, we engineered a bioconjugate nanovaccine (Fn-OPS) through a bacterial glycosylation-driven synthetic strategy, which couples Yersinia enterocolitica O:9 (YeO9) O-specific polysaccharide (OPS)a structural analogue of Brucella antigensto a self-assembled ferritin nanoparticle (Fn). This nanocarrier platform combines the symmetrical architecture and antigen-presenting advantages of Fn with the precision of enzymatic glycosylation, addressing the limitations of complex chemical synthesis methods. After confirming the presence of monodisperse nanoparticles with stability at room temperature and great in vivo safety, we performed murine immunization studies and demonstrated a robust activation of T follicular helper (Tfh) cells and germinal center B cells, leading to the production of high-titer IgG antibodies that are cross-reactive with Brucella lipopolysaccharide. This immune response provides strong protection against Brucella infection. This work establishes a ferritin-based nanoconjugate platform for targeted delivery of complex polysaccharide antigens. It advances a scalable, biosafe strategy for Brucella vaccines, expanding the toolkit for targeted antigen delivery in conjugate vaccine design and broadening applications in infectious disease prophylaxis.

Keywords: conjugate vaccines, Brucella abortus, ferritin, bioengineering, synthetic biology, PGCT


graphic file with name id5c00260_0007.jpg


graphic file with name id5c00260_0005.jpg


Brucellosis, caused by Brucella, is one of the most prevalent zoonotic diseases worldwide. It is particularly common in livestock regions, significantly impacting human health and the development of the livestock industry. In humans, Brucella infection can lead to a range of symptoms, including undulant fever, hepatosplenomegaly, joint pain, and reproductive organ damage. There are a reported 500,000 incident cases of human brucellosis per year. However, true incidence is estimated to be 5,000,000 to 12,500,000 cases annually. Furthermore, treating Brucella infections with antibiotics is challenging due to the bacteria’s intracellular nature. Research on vaccines for Brucella has primarily focused on the development of inactivated and attenuated vaccines. While these vaccines are somewhat effective in controlling Brucella infections, they also have limitations, such as the potential risk of human infection and the possibility of causing abortion in pregnant cattle. ,

Conjugate vaccines, which are produced by covalently coupling bacterial polysaccharide antigens with carrier proteins, represent one of the most successful categories of bacterial vaccines. These vaccines can transform polysaccharide antigens, which are T-cell-independent, into T-cell-dependent antigens. This transformation enables both T cells and B cells to participate in the immune response, resulting in long-lasting immune memory. Generally, conjugate vaccines can be synthesized using both chemical and biological methods. Although the currently listed varieties are all synthesized through chemical methods, their preparation processes are complex, involving multiple purification and separation steps. As a result, these methods exhibit characteristics such as high costs and poor uniformity, which limit their development. The biological synthesis of polysaccharide conjugate vaccines primarily employs Protein-Glycan Coupling Technology (PGCT), which involves a series of enzyme-catalyzed reactions conducted in engineered strains to synthesize glycoproteins. , Typically, the target polysaccharide antigen, carrier protein, and glycosyltransferase are coexpressed in engineered Escherichia coli , allowing the polysaccharide to be coupled with the carrier protein under the catalysis of glycosyltransferases. In this process, glycosyltransferase plays a crucial role, as it must be capable of recognizing polysaccharides from various bacterial sources. The first glycosyltransferase reported for conjugate vaccine preparation was PglB, derived from Campylobacter jejuni. Subsequently, another glycosyltransferase, PglL, which exhibits broader substrate specificity, was identified. PglL, derived from Neisseria meningitidis , can recognize nearly all OPS. In our previous work, we demonstrated the feasibility of this system for the preparation of vaccines against different pathogens. −

Although this system can also be utilized for the preparation of Brucella conjugate vaccines, the genes encoding the Brucella OPS are not yet fully understood. Additionally, another strategy involving the direct transfer of the glycosylation system into Brucella presents significant biosafety risks. In recent years, due to the structural similarities of OPS between Brucella and YeO9, an alternative method has been developed to address these challenges. Through PGCT, the OPS gene cluster from YeO9 can be cloned into E. coli , allowing the production of a vaccine that provides protection against Brucella. Numerous studies have demonstrated the efficacy of YeO9 OPS antibodies in preventing Brucella infections. ,,

In conjugate vaccines, the carrier components play a crucial role in eliciting the polysaccharide antibody response. With the advancement of nanotechnology, nanoparticles are increasingly utilized as carriers in vaccine design due to their robust delivery capabilities and advantages in immune activation. − Among these, proteinaceous nanocarrierssuch as virus-like particles, ferritin, and other self-assembling particleshave garnered significant attention because of their enhanced safety and biocompatibility. − Ferritin is a hollow spherical nanoparticle composed of 24 self-assembling subunits. Numerous studies have demonstrated that ferritin nanoparticles can stimulate a strong immune response and have been developed as candidate vaccines against various pathogens, including COVID-19, influenza, and hepatitis B. − However, to our knowledge, there are few reports on the application of ferritin nanoparticles in bacterial vaccine design, particularly concerning the immune activation of polysaccharide antigens.

To further expand the application of ferritin nanoparticles and establish an effective prevention strategy against Brucella infection, we developed a candidate bioconjugate nanovaccine (Fn-OPS) targeting Brucella through PGCT in engineered E. coli , utilizing ferritin particles as carriers. Our findings indicate that glycosylation does not interfere with the self-assembly of ferritin, and the glycoprotein exhibits good stability. After confirming the safety of Fn-OPS, we conducted a series of animal experiments, which revealed that ferritin nanoparticles can stimulate the proliferation of Tfh cells and germinal center (GC) B cells, resulting in a robust antibody response. Furthermore, we observed that mice immunized with Fn-OPS exhibited strong protective effects in both lethal and nonlethal infection models. This study offers a safe and effective strategy for the development of Brucella vaccines, thereby expanding the library of carriers for conjugate vaccines and enhancing the design of conjugate vaccines.

Results

Biosynthesis of Fn-OPS in Engineered E. coli

Our previous research has demonstrated the universal applicability of the PglL glycosylation system in the preparation of bacterial conjugate vaccines. Encouraged by the significant advantages of ferritin in stimulating immune responses and its widespread application in vaccine development, we aimed to biosynthesize a novel and efficient Brucella conjugate vaccine using ferritin nanoparticles as carriers. First, the plasmid pET28a-PglL-Fn, designed for the coexpression of PglL and ferritin under the induction of IPTG, was constructed. Subsequently, both plasmids, pET28a-PglL-Fn and pACYC184-OPS (which expresses YeO9 OPS), were introduced into the previously engineered E. coli W3110△waaL△wbbH-L, which is conducive to the expression of exogenous polysaccharides (Figure a). After induction with IPTG, whole-cell samples were analyzed by SDS-PAGE, and glycosylation was verified through Western blotting using an HRP-labeled 6× His tag antibody. The results demonstrated a distinct upward migration of ferritin monomers, appearing as typical glycoprotein ladder-like bands within a size range of 30–50 kDa when coexpressed with PglL and OPS, indicating the successful coupling of ferritin and OPS (Figures b and S1).

1.

1

Characterization of Fn-OPS. (a) Schematic diagram of Fn-OPS preparation: ferritin, PglL, and the OPS glycan cluster are coexpressed in engineered E. coli . During this process, the OPS is expected to be coupled with the ferritin nanoparticle under the catalysis of PglL in the periplasm. Subsequently, the Fn-OPS conjugate is obtained through purification. (b) Coomassie blue staining and immunoblotting analysis of glycoprotein expression using an HRP-labeled 6 × His tag antibody. (c) Coomassie blue staining and immunoblotting analysis of purified Fn-OPS using HRP-labeled 6 × His tag antibody and anti-Brucella serum. (d) Retention volume of Fn-OPS in size-exclusion chromatography (Superdex 200, 24 mL column). (e) Representative TEM image of purified Fn-OPS. (f) DLS analysis of Fn-OPS. (g) Stability of Fn-OPS at room temperature was evaluated through DLS over time (n = 3).

After purification through Ni2+ affinity chromatography and size-exclusion chromatography, the glycoprotein (Fn-OPS) was further validated using Coomassie blue staining and Western blotting with HRP-labeled 6 × His tag antibody and anti-Brucella serum. The results of Coomassie blue staining indicated that the purity of Fn-OPS exceeded 80%, and the bands were consistent with those observed in the whole-cell samples (Figures c and S2). Although Fn-OPS exhibited a relatively low molecular weight in the SDS-PAGE results, its retention volume was approximately 7–8 mL from a 24 mL column volume of Superdex 200 gel during size-exclusion chromatography, suggesting that Fn-OPS is a polymer (Figure d). Transmission electron microscopy (TEM) revealed that the particle size of Fn-OPS was approximately 22 nm (Figure e). Additionally, dynamic light scattering (DLS) results demonstrated a monodisperse distribution with a consistent particle size, corroborating the TEM findings (Figure f). To assess the stability of Fn-OPS, the solution was stored at room temperature and monitored through DLS and Coomassie blue staining over a continuous period of 7 days. The results indicated that the particle size remained stable at around 22 nm (Figure g, Table S1), and the molecular size remained between 30 and 50 kDa (Figure S3), demonstrating the good stability of the glycoprotein.

Safety Assessment of the Fn-OPS

Before animal immunization, we first evaluated the safety of Fn-OPS. Mice were injected with ten times the normal immune dose of polysaccharide (25 μg), while the control group received no treatment. Prior to injection, we quantified the endotoxin content in the samples. The calculated dose administered per mouse was approximately 0.12 EU, which falls within the permissible limit for endotoxin content as stipulated by the Chinese Pharmacopoeia. However, it remains unclear whether this level could influence the readings of cytokines and other indicators. During the observation period, we monitored a series of safety indicators, including temperature, weight, serum inflammatory factors, biochemical indicators, and pathological sections of organs (Figure a). We found that within 14 days after immunization, there were no significant changes in body temperature and weight between the two groups (Figure b,c). We also measured the levels of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the serum of each mouse and observed very low concentrations with no significant differences between the vaccine and control groups (Figure d). By assessing serum biochemical indicators, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), and lactate dehydrogenase (LDH) on day 28 postimmunization, we found that all indicators in the vaccine group were within the normal range (Figure e). Pathological section analysis of the heart, liver, spleen, lung, and kidney, stained with hematoxylin and eosin (HE), showed no pathological damage in the organs of the vaccine group (Figure f). These results indicate that Fn-OPS is safe for use.

2.

2

Safety evaluation of Fn-OPS in mice. (a) Monitoring of safety indicators: Mice were subcutaneously injected with Fn-OPS (10 times the conventional dose) or PBS (control). A series of indicators were tracked at multiple time points. (b, c) Temperature (b) and weight (c) in mice were measured (n = 5). (d) Serum inflammatory factors (IFN-γ (n = 4), TNF-α (n = 3), IL-1β (n = 5), and IL-6 (n = 4)) were detected at indicated time points. (e) Serum biochemical markers (ALT, AST, ALP, BUN, and LDH) on day 28 postinjection (n = 5). (f) HE-stained tissue sections (heart, liver, spleen, lung, and kidney) were analyzed. The data are presented as means ± SD.

Fn-OPS Induced Strong Immune Response and Provided Protection against Lethal Infections of B. abortus A19

The GC, recognized as the primary site for B cell responses to antigens, is formed through the rapid division and proliferation of activated B cells. The formation of GCs requires significant assistance, particularly from Tfh cells, which are essential for GC development and play a crucial role in regulating the differentiation of B cells into plasma cells and memory B cells. , To evaluate the humoral immune response to Fn-OPS, we first analyzed the proliferation of Tfh and GC B cells in vivo. Mice were subcutaneously injected with PBS, OPS alone, or Fn-OPS. Ten days postinjection, the lymph nodes and spleens from each mouse were harvested, and the proportions of lymph node and splenic Tfh and GC B cells were analyzed using flow cytometry. The results indicated that the proportion of Tfh cells in the Fn-OPS group showed a significant increase compared to both the OPS and PBS groups (Figures b, S5, and S6). Additionally, the proportion of GC B cells in the Fn-OPS group also demonstrated a notable increase compared to the OPS and PBS groups (Figures c, S5, and S6). These findings suggest that Fn-OPS effectively stimulates the activation of the humoral immune response in mice.

3.

3

Immune cell activation, antibody response, and protection against lethal B. abortus infection. (a) Immunization schedule for evaluating of Fn-OPS efficacy. (b, c) Flow cytometry analysis of lymph node Tfh cells (CXCR5+PD-1+ in CD4+ cells) (b) and GC B cells (GL7+CD95+ in CD45R+ cells) (c) on day 10 postimmunization (n = 3). (d) Serum IgG titers against B. abortus A19 LPS on day 7 after each immunization (n = 10). (e, f) IgG subtype titers (IgG1 and IgG2a) on day 35 post-third immunization (n = 10). (g) Survival of mice challenged intraperitoneally with B. abortus A19 (2.6 × 108 CFU/mouse) on day 14 postimmunization (n = 10). The data were presented as means ± SD. Statistical analysis was performed using one-way analysis of variance with Dunn’s multiple comparison test (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). The specific data related to the statistical analysis are provided in Table S3a–e.

To determine the specific antibodies against OPS, BALB/c mice were divided into five groups and subcutaneously immunized on days 0, 14, and 28 with PBS, OPS, Fn+OPS (a physical mixture of Fn and OPS), Fn-OPS, or Fn-OPS combined with aluminum hydroxide adjuvant (Al), using 2.5 μg of polysaccharide for each candidate (Figure a). Seven days postimmunization, tail blood was collected, and the IgG antibody titers against B. abortus A19 Lipopolysaccharide (LPS) in serum were measured using ELISA. The results indicated that all groups containing OPS (including OPS, Fn+OPS, Fn-OPS, and Fn-OPS+Al) could induce a specific antibody response, with the Fn-OPS and Fn-OPS+Al groups demonstrating the most efficient stimulation (Figure d). We further assessed the titers of IgG subtypes (IgG1 and IgG2a) in serum on day 35. Notably, both subtypes were enhanced when OPS was conjugated to Fn, while OPS alone or mixed with Fn did not show significant improvement (Figure e,f). These results suggest that a strong specific immune response can be induced by Fn-OPS.

To evaluate the protective effect of this bioconjugate nanovaccine, all mice were challenged intraperitoneally with B. abortus A19 (2.6 × 108 CFU/mouse) on day 42, which was 14 days after the third immunization. The survival of each mouse was monitored. During the 7-day observation period, all mice in the PBS, OPS, and Fn+OPS groups died within 3 days, while the protective efficacy of Fn-OPS and Fn-OPS+Al reached 60 and 80%, respectively (Figure g).

Fn-OPS Provided Protection against Nonlethal Infections of B. abortus A19

Encouraged by the robust protection provided by Fn-OPS against lethal infections, we further evaluated additional indicators at nonlethal doses, which are more representative of actual infections. The grouping and immunization methods were consistent with those described previously. Fourteen days after the third immunization, each mouse was injected intraperitoneally with B. abortus A19 (2.84 × 107 CFU/mouse) (Figure a). To monitor the cytokine levels following infection, tail blood was collected on days 0, 1, 3, 5, and 7 postchallenge, and the concentrations of TNF-α, IFN-γ, and IL-6 at each time point were measured using ELISA (Figure b). The results indicated that both Fn-OPS and Fn-OPS+Al treated mice maintained lower levels of the three inflammatory cytokines, while the PBS, OPS, and Fn+OPS groups exhibited significant increases, particularly on the third day after infection.

4.

4

Protective efficacy of Fn-OPS against nonlethal B. abortus infection. (a) Schematic of experimental design for nonlethal infection assessment. (b) Serum cytokine levels (IL-6, IFN-γ, and TNF-α) were detected on days 0, 1, 3, 5, 7 postchallenge (n = 3). (c) Spleen weight of each mouse was measured on day 7 postinfection (n = 5). (d) Splenic bacterial loads were counted on day 7 postinfection (n = 5). (e, f) HE-stained spleen (e) and liver (f) sections on day 45 postinfection. The data were presented as means ± SD. Statistical analysis was performed using one-way analysis of variance with Dunn’s multiple comparison test (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). The specific data related to the statistical analysis are provided in Table S3f–h.

Seven days postinfection, the mice were humanely euthanized, and their spleens were weighed. It was observed that the mice treated with Fn-OPSs exhibited the least change in both weight and size of the spleen, showing almost no effect even when aluminum adjuvant was added. In contrast, the PBS, OPS, and Fn+OPS groups displayed significant spleen enlargement (Figures c and S2). Additionally, the bacterial load in the spleen was measured. Notably, compared to the PBS group, the spleen bacterial load in the Fn-OPS and Fn-OPS+Al groups decreased by 1.5 and 2 orders of magnitude, respectively, indicating a robust bacterial clearance capability (Figure d). Pathological sections of the spleen stained with hematoxylin and eosin (HE) revealed a clear separation between red and white pulp in the nanovaccine groups, with fewer multinucleated giant cells and a reduced inflammatory response (Figure e). The liver pathology results were consistent with those of the spleen (Figure f).

Discussion

A safe and effective Brucella vaccine is essential for preventing brucellosis; however, there is currently no commercially available Brucella vaccine for human use. In this study, we developed a novel bioconjugate nanovaccine candidate (Fn-OPS) for Brucella by utilizing YeO9 OPS as the antigen, which has a structure similar to that of Brucella polysaccharide. The YeO9 OPS was conjugated to the surface of a ferritin nanoparticle, a widely used delivery carrier, through PGCT in engineered E. coli . This vaccine has reached the nanoscale and can maintain stability at room temperature for an extended period. Animal experiments also confirmed that Fn-OPS is safe and can stimulate a strong specific antibody response. Notably, it provided significant protection in both lethal and nonlethal infection models.

Currently, there are two primary strategies for the biosynthesis of conjugate vaccines using PGCT. The first strategy involves direct synthesis within attenuated pathogenic bacteria. By knocking out the O-antigen ligase gene in these bacteria, the OPS cannot be converted to Lipid A-core; instead, it is linked to the carrier protein under the catalysis of glycosyltransferase. This approach is applicable when the gene cluster for the pathogen’s polysaccharide is not well understood, although it still poses safety risks during the preparation process. Another strategy, also adopted in this study, utilizes engineered E. coli as the host organism. In this approach, genes associated with OPS synthesis from pathogenic bacteria are cloned and transferred into E. coli. There are several advantages to heterologous expression. First, E. coli is a nonpathogenic bacterium, which minimizes the use of pathogenic bacteria and enhances the safety of vaccine production. Second, E. coli has a short cultivation cycle and relatively simple culture conditions. Finally, the E. coli expression system is efficient and easy to manipulate, making it a more advantageous choice for industrial production. However, compared to the first strategy, the efficiency of synthesizing exogenous polysaccharides in E. coli may be lower. Therefore, engineering modifications, such as the deletion of its native polysaccharide synthesis genes and optimization of metabolic pathways, are necessary.

Although the gene cluster responsible for the synthesis of OPS in Brucella is not clearly defined, studies have demonstrated that the OPS of Brucella abortus exhibits cross-reactivity with the OPS of YeO9. The structure of Brucella OPS is characterized as a block copolymer composed of 4,6-dideoxy-4-formamido-d-mannopyranosyl (d-Rha4NFo) sugars, which are primarily linked by α-1,2 bonds (A antigen), but also contain a variable ratio of α-1,3 linkages (M antigen). The proportion of each linkage type in different strains of Brucella appears to vary, with α-1,3 linkages constituting between 0 and 20%, while the remainder consists of α-1,2 linkages (A antigen). The OPS of YeO9 is a homopolymer that consists exclusively of α-1,2 linked d-Rha4NFo units, which are identical to the Brucella A antigen. It is considered to be nearly identical to that of Brucella, containing over 98 and 80% A antigen in B. abortus and B. melitensis OPS, respectively. Previous research has also confirmed that antibodies against YeO9 OPS have a protective effect against Brucella infection. Previous studies have demonstrated that antibodies targeting Brucella surface polysaccharides are protective, suggesting the potential for polysaccharide-based vaccine development. For instance, studies have employed smooth lipopolysaccharide (sLPS) derived from Brucella abortus S19, combined with Quillaja saponin (QS) or its mixture with xyloglucan (QS-X), to evaluate the efficacy and safety of vaccines against respiratory brucellosis. This vaccine combination was shown to induce a robust immune response and significantly reduce the bacterial load within the spleens of mice challenged with Brucella abortus S19. Collectively, these findings demonstrate that Brucella OPS functions as a key immunodominant antigen. It is able to effectively elicit protective immune responses within the host, thereby mediating effective defense against Brucella infection. In this study, we substituted the polysaccharide of Yersinia enterocolitica O:9 (YeO9 OPS) for that of Brucella, capitalizing on their structural similarity. Our results are consistent with the finding.

The immune effects produced by polysaccharide antigens alone are relatively weak, necessitating their combination with carrier proteins to enhance immunogenicity. Nanoparticles, which range in shape and size from a few to several hundred nanometers, are commonly utilized as protein carriers in vaccines and demonstrate significant potential. , The primary advantages of nanoparticle vaccines include their ability to protect the antigen from premature degradation, thereby enhancing the stability of the vaccine, and their capacity to provide adjuvant effects, facilitating the targeted delivery of the antigen to antigen-presenting cells. , Compared to monomeric vaccines, nanoparticle vaccines can stimulate the host to produce a greater quantity of neutralizing antibodies and generate a stronger immune response. Currently, commonly used nanoparticles include virus-like particles (VLPs), biodegradable and biocompatible polymers, and liposomes, which offer numerous advantages as vaccine delivery platforms due to their unique physicochemical properties. − Among these, self-assembling ferritin stands out as an ideal platform for antigen presentation. Ferritin is found in most biological tissues, including those of bacteria, fungi, plants, and animals. Ferritin nanoparticles possess a hollow spherical structure with an inner diameter of 8 nm and an outer diameter of 12 nm. Their repetitive symmetric structure and rich surface features can induce a robust immune response. , Although the high-dose B. abortus A19 challenge does not represent a realistic infection, it remains a stringent preliminary screening tool. The critical evidence comes from our low-dose model, where vaccination resulted in a significant (∼2-log) reduction in bacterial burden. This demonstrates a robust ability to control an established infection, indicating that the vaccine elicits functional and relevant protective immunity. Additionally, their inherent stability allows vaccine formulations to resist thermal degradation, potentially reducing cold-chain dependencya critical advantage for global distribution.

In this study, we successfully prepared a nano scaled conjugate vaccine using ferritin nanoparticles as carriers and demonstrated excellent efficacy. However, our research on saccharide loading and glycan chain length in conjugate vaccines remains insufficient. In future studies, we will further optimize key parameters including polymer molecular weight, monosaccharide composition, purity, and antigen density ratio, to advance the vaccine toward clinical application. In addition, other nanocarriers, such as VLPs, I53-50, metal–organic and covalent organic frameworks also show strong potential in enhancing vaccine efficacy. Given that our bioconjugate nanovaccines utilize a proteinaceous scaffold and achieve significant protective efficacy, future studies could explore several directions. For instance, due to the strong immune activation ability of ferritin, it can be used as a carrier to couple OPS of other pathogens to prepare candidate vaccines. This rapid polysaccharide protein coupling technology avoids the shortcomings of traditional chemical methods and can promote the development of conjugate vaccines. In addition, bioorthogonal platforms (e.g., SpyCatcher/SpyTag or biotin/streptavidin) could be leveraged to load additional antigens onto nanocarrier. The combination of bioorthogonal system and glycosylation system can modularize the vaccine preparation method and promote the universality of this system. Besides, unlike intramuscular/subcutaneous injections, microneedle patches enable pain-free cutaneous vaccine delivery. This method eliminates requirements for cold-chain storage and trained personnel, promoting accessibilityparticularly in resource-limited regions with high infectious disease prevalence.

Conclusions

In this study, we successfully engineered a novel bioconjugate nanovaccine, Fn-OPS, by integrating nanoscale ferritin carriers with YeO9 OPSsimilar in structure to Brucella antigensvia a biological glycosylation system in E. coli . This nanovaccine leverages ferritin’s self-assembly and enhanced antigen presentation, offering a biosafe and scalable alternative. Mechanistic evaluations revealed that Fn-OPS robustly activates T-cell-dependent immunity. Crucially, Fn-OPS elicited high IgG antibodies titer cross-reactive with Brucella lipopolysaccharide, and demonstrated great protective in both lethal and nonlethal Brucella challenges. These outcomes highlight its potential as a prophylactic candidate for both veterinary and human applications. Furthermore, the use of PGCT ensures precise antigen-carrier conjugation, circumventing the inefficiencies of chemical synthesis. Future studies will focus on optimizing antigen density on ferritin scaffolds, evaluating long-term immune memory, and exploring applications of this platform for other zoonotic diseases. In this study, we successfully engineered a novel bioconjugate nanovaccine, Fn-OPS, by integrating nanoscale ferritin carriers with Yersinia enterocolitica O:9 OPSsimilar in structure to Brucella antigensvia a biological glycosylation system in E. coli . This nanovaccine leverages ferritin’s self-assembly and enhanced antigen presentation, offering a biosafe and scalable alternative. Mechanistic evaluations revealed that Fn-OPS robustly activates T-cell-dependent immunity. Crucially, Fn-OPS elicited high IgG antibodies titer cross-reactive with Brucella lipopolysaccharide, and demonstrated great protective in both lethal and nonlethal Brucella challenges. These outcomes highlight its potential as a prophylactic candidate for both veterinary and human applications. Furthermore, the use of PGCT ensures precise antigen-carrier conjugation, circumventing the inefficiencies of chemical synthesis. Future studies will focus on optimizing antigen density on ferritin scaffolds, evaluating long-term immune memory, and exploring applications of this platform for other zoonotic diseases.

Materials and Methods

Strains, Plasmids, and Culture Conditions

E. coli W3110ΔwaaLΔwbbH-L is an engineered strain of E. coli W3110 that lacks the genes waaL, wbbH, wbbJ, wbbK, and wbbL. Brucella abortus A19 is an attenuated strain of Brucella abortus as reported before. YeO9 is Yersinia enterocolitica serotype O:9 with an O antigenhe (The NCBI accession numbers of YeO9 OPS gene cluster, AJ605741.1) that shares the same antigen structure as B. abortus A19. The plasmid pET28a-pglL-Fn having been constructed for this experiment (Figure S7). Briefly, Pseudomonas aeruginosa ferritin sequence (The NCBI accession numbers of Fn, WP_139274952.1) was synthesized and then amplified with primers (forward primer: 5′-CGAGCTCTGCATAATTCGTGTCGCTC-3′; reverse primer: 5′-CCTCGAGCTTGATCTCACTGCTT-3′). Then the fragment was digested with restriction enzymes SacI and XhoI, and it was then ligated into the pET28a-PglL-SpyCatcher (The NCBI accession numbers of SpyCatcher, JQ478411.1) vector (precleaved with the same enzymes) using T4 DNA ligase. After being transferred to DH5α and incubated overnight at 37 °C, single colonies were selected and sequenced to determine the correct plasmid. The plasmid pET28a-PglL-Fn enables the coexpression of ferritin (Fn) and the glycosyltransferase PglL. To facilitate periplasmic localization, the DsbA signal peptide (The NCBI accession numbers of DsbA, MDU1272422.1) was fused to the N-terminus of ferritin. Subsequently, a previously reported glycosylation tag (designated 4573) was fused to its C-terminus to enable glycosylation. A 6 × His tag was incorporated at the C-terminal end of this tag for detection and purification purposes. Concurrently, the plasmid pET28a-PglL-Fn expresses the glycosyltransferase PglL, this enzyme recognizes the bacterial O-specific polysaccharide (OPS) and catalyzes its ligation to the serine residue within the glycosylation tag (4573), thus enabling the synthesis of the target glycoprotein. The plasmid pACYC184-OPS (laboratory stock) encodes the OPS of YeO9, conferring chloramphenicol resistance. The detailed information and schematic diagrams of the plasmids used in this study are provided in Table S2 and Figure S8.

The E. coli W3110 series strains were cultured at 37 °C in liquid Luria–Bertani (LB) medium or on LB agar plates containing 1.5% agar. YeO9 was cultured at 30 °C in Brain-Heart Infusion (BHI) medium with 1.5% agar, while B. abortus A19 was cultured in Tryptic Soy Broth (TSB) or on TSB agar plates with 1.5% agar at 37 °C. For protein expression, strains carrying the expression plasmids were cultured at 37 °C to an optical density (OD600 nm) of approximately 0.6. Subsequently, isopropyl β-d-1-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM, and the culture was incubated at 30 °C for 12 h.

Purification of Glycoproteins

Cells were collected by centrifugation at 8,000 rpm for 10 min at 4 °C and then resuspended in buffer A1 (20 mM Tris-HCl, pH 7.5, 10 mM imidazole, 500 mM NaCl). The cells were lysed using a homogenizer, and the supernatant was collected via centrifugation. This supernatant was then passed through a chelating column (Complete His-Tag Purification Resin, Roche, Penzberg, Germany). After washing with buffer A1, the bound proteins were eluted with buffer B1 (20 mM Tris-HCl, pH 7.5, 500 mM imidazole, 500 mM NaCl). The sample was further purified using a Sephadex 200 column (GE Healthcare) and analyzed by SDS-PAGE. After confirming the glycoproteins through Coomassie blue staining, the eluted solution was concentrated using ultrafiltration. Then, the product was loaded onto a Superdex 200 prep grade column (GE Healthcare, Chicago, 24 mL, USA) using PBS as the mobile phase at 1 mL/min. The protein solution was collected sequentially and verified through Coomassie blue staining.

Western Blot Analysis

The 6 × His-tagged proteins were detected using horseradish peroxidase (HRP)-conjugated 6 × His-tag antibodies (Abmart, Shanghai, China) at a dilution of 1:3000. Rabbit anti-Brucella antibody (Youke, Shanghai, China) was used to detect the glycoproteins at a dilution of 1:50, with HRP-conjugated antirabbit IgG (Transgen Biotec Company, Beijing, China) at a dilution of 1:15,000 as the secondary antibody.

Extraction of LPS and OPS

Bacteria were collected by centrifugation and resuspended in ddH2O. An equal volume of 90% phenol was added, and the mixture was vigorously shaken at 68 °C for 30 min. Following centrifugation at 8000 rpm for 20 min at 4 °C, the supernatant was collected. The phenol in the supernatant was removed using a dialysis bag in ddH2O for 2 days. Subsequently, DNase (5 μg/mL), RNase (1 μg/mL), and proteinase K (20 μg/mL) were added sequentially to the dialyzed sample. After incubation at the optimal temperature, the solution was boiled for 10 min and centrifuged at 8000 rpm for 10 min to obtain the LPS. Glacial acetic acid was added to the LPS solution to achieve a final concentration of 1%, and the solution was boiled for 90 min before adjusting the pH to 7.0. After centrifugation at 40,000 g for 5 h, the supernatant was collected to yield the OPS.

Experimental Animals

Pathogen-free female BALB/c mice (6–8 weeks old) were purchased from SPF Biotechnology (Beijing, China) and housed at the Laboratory Animal Centre of the Academy of Military Medical Sciences. All of the animal experiments were approved by the Academy of Military Medical Sciences Animal Care and Use Committee (Ethics Approval Code IACUC-SWGCYJS-2024–034) and conducted in accordance with the ACS Ethical Guidelines. The animals were maintained under controlled conditions (temperature: 23 ± 2 °C, humidity: 55 ± 5%) with bedding, feed, and water replaced every 4 days. Group sizes were determined in accordance with the 3R principle and with reference to established standards. Challenge experiments were performed in a Biosafety Level 2 (BSL-2) laboratory. For the lethal challenge, explicit humane end points were not defined due to the rapid progression of septicemia following intraperitoneal infection with Brucella, which often results in acute mortality. Monitoring was carried out every 6 h on the first day postchallenge and every 12 h thereafter, with deceased animals removed promptly. In nonlethal challenges, humane euthanasia was administered if mice exhibited rapid weight loss of 15–20% or prolonged immobility.

Animal Immunization and Challenge

BALB/c mice were immunized via subcutaneous injection of the vaccine on days 0, 14, and 28. The vaccines included Fn-OPS+Al (2.5 μg polysaccharide), Fn-OPS (2.5 μg polysaccharide), Fn+OPS (2.5 μg polysaccharide), OPS (2.5 μg polysaccharide), and PBS. Blood samples were collected from the tail vein of each mouse on the seventh day following each injection, and serum was isolated. On day 42, the challenge bacteria were cultured in TSB medium at 37 °C until the OD600 reached 1.0. The bacteria were then diluted to the desired concentration with saline. The diluted bacteria were injected intraperitoneally into the mice at a volume of 200 μL per mouse.

ELISA

First, 100 μL of Brucella A19 LPS (100 μg/mL) was coated onto a 96-well plate and incubated overnight at 4 °C. The plates were washed three times with PBST, after which 200 μL of blocking buffer (5% skim milk in PBST) was added to each well and incubated at 37 °C for 2 h. Following the blocking step, serum from each mouse was added to the corresponding wells, serially diluted with dilution buffer (10% blocking buffer), and incubated at 37 °C for 1 h. The plates were washed again, and 100 μL of HRP-conjugated donkey antimouse IgG, IgG1, and IgG2a antibodies (Abcam, Cambridge, MA, USA), diluted to 1:15,000, were added to each well and incubated at 37 °C for 1 h. After washing, the color was developed using a TMB kit (CWBIO, Beijing, China), and the OD value was measured at a wavelength of 450 nm using a spectrophotometer.

Bacterial Load in the Spleen

Fourteen days after the third immunization, each mouse was intraperitoneally injected with 2.84 × 107 CFU of the B. abortus A19 strain. Seven days postinfection, the mice were humanely euthanized, and their spleens were collected and weighed. The spleens were then homogenized in 2 mL of sterile saline. The homogenized spleen samples were serially diluted with sterile saline and plated on TSA solid medium, which was incubated at 37 °C for 72 h. Subsequently, the bacterial colonies were counted.

Flow Cytometric Analysis of Lymph Node and Spleen Cells

Mice were humanely euthanized, and their lymph nodes and spleens were removed. The lymph nodes (dLNs) were triturated to generate single-cell suspensions using DPBS containing 1% fetal bovine serum (FBS). The spleens were homogenized, and red blood cells were removed using RBC lysis buffer (Solarbio) according to the manufacturer’s instructions. After centrifugation at 500 g for 10 min at 4 °C, the supernatant was discarded, and the cells were resuspended and washed twice with staining buffer (eBioscience) to obtain a single-cell suspension. The cells were then stained with various combinations of flow cytometry antibodies: APC-conjugated antimouse CD45R (eBioscience, San Diego, United States), AF488-conjugated antimouse GL-7 (eBioscience), PE-conjugated antimouse CD95 (eBioscience), FITC-conjugated antimouse CD4 (eBioscience), PE-conjugated antimouse PD-1 (eBioscience), and APC-conjugated antimouse CXCR5 (eBioscience). After staining, the cells were washed with staining buffer, and 500 μL of staining buffer was added. The analysis was performed using a MoFlo CytoFLEX flow cytometer (Beckman Coulter Life Sciences, Brea, USA).

Data Analysis

Data are presented as mean ± standard deviation. Statistical analyses were conducted using GraphPad Prism 8.0 (GraphPad, San Diego, CA, USA). One-way analysis of variance (ANOVA) and Dunn’s multiple comparison test were employed for comparisons among multiple groups. A p-value of less than 0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Supplementary Material

id5c00260_si_001.pdf (856.3KB, pdf)

Acknowledgments

This work was supported by National Key Research and Development Program of China (2023YFC2307703 and 2021YFC2102100), National Natural Science Foundation of China (92478116), Beijing Natural Science Foundation (7252170), and Beijing Nova Program: (20220484072 and 20240484724).

Glossary

Abbreviations Used

OPS

O-specific polysaccharide

Fn

Ferritn

Tfh

T follicular helper

TEM

Transmission Electron Microscopy

DLS

Dynamic Light Scattering

IPTG

isopropyl-β-d-thiogalactopyranoside

TNF-α

tumor necrosis factor-alpha

IFN-γ

interferon-gamma

IL-6

interleukin-6

IL-1β

interleukin-1β

ALT

alanine aminotransferase

AST

aspartate aminotransferase

ALP

alanine aminotransferase

BUN

blood urea nitrogen

LDH

lactate dehydrogenase

Al

aluminum hydroxide adjuvant

LPS

Lipopolysaccharide

HE

hematoxylin and eosin

VLPs

virus-like particles

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.5c00260.

  • Figure S1, the raw gels and blots for Figure b; Figure S2, the raw gels and blots for Figure c; Figure S3, coomassie blue staining of Fn-OPS stored at room for 7 days; Figure S4, appearance of the spleen removed from the mouse after a nonlethal challenge; Figure S5, analysis of immune response in spleen; flow cytometry analysis of splenic Tfh cells (CXCR5+PD-1+ in CD4+ cells) (a) and GC B cells (GL7+CD95+ in CD45R+ cells) (b) on day 10 postimmunization (n = 3); Figure S6, the flow cytometry gating strategy for Tfh and GC B Cells of Fn-OPS immunized mice; Figure S7, plasmid construction of pET28a-PglL-Fn; SpyCatcher sequence was replaced with that of ferritin (Fn); Figure S8, plasmid maps used in this study (a) plamid maps of pET28a-PglL-SpyCatcher, (b) plasmid maps of pACYC184tac-OPS, and (c) plasmid maps of pET28a-PglL-Fn; Table S1, quantitative stability data for Figure g; Table S2, bacterial plasmids used in this study; and Table S3, supporting statistical data in this study (including several tables) (PDF)

W.L., J.L., X.C., and C.P. designed the experiments. W.L., J.L., T.L., and J.Y. performed the experiments. N.S. and Z.C. performed data collation and investigations. Y.L., Z.L., and X.Y. performed the theoretical analyses. W.L., T.L., and C.P. prepared the original draft, reviewed, and edited the manuscript. H.W., ZL, Y.W., and C.P. supervised the work, undertook project administration, and acquired funding. W.L., J.L., and X.C. contributed equally to this work.

The authors declare no competing financial interest.

References

  1. Huang J., Guo Y., Yu S., Wang D., Li S., Wu J., Sun P., Zhu L., Wang H., Pan C.. One-step preparation of a self-assembled bioconjugate nanovaccine against Brucella . Virulence. 2023;14(1):2280377. doi: 10.1080/21505594.2023.2280377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hull N. C., Schumaker B. A.. Comparisons of brucellosis between human and veterinary medicine. Infect. Ecol. Epidemiol. 2018;8(1):1500846. doi: 10.1080/20008686.2018.1500846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ariza J., Bosilkovski M., Cascio A., Colmenero J. D., Corbel M. J., Falagas M. E., Memish Z. A., Roushan M. R. H., Rubinstein E., Sipsas N. V., Solera J., Young E. J., Pappas G.. Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations. PLoS Med. 2007;4(12):e317. doi: 10.1371/journal.pmed.0040317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Avila-Calderón E. D., Lopez-Merino A., Sriranganathan N., Boyle S. M., Contreras-Rodríguez A.. A History of the Development ofBrucellaVaccines. BioMed. Res. Int. 2013;2013:1–8. doi: 10.1155/2013/743509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dorneles E. M. S., Sriranganathan N., Lage A. P.. Recent advances in Brucella abortus vaccines. Vet. Res. 2015;46(1):76. doi: 10.1186/s13567-015-0199-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Rappuoli R.. Glycoconjugate vaccines: Principles and mechanisms. Sci. Transl. Med. 2018;10(456):eaat4615. doi: 10.1126/scitranslmed.aat4615. [DOI] [PubMed] [Google Scholar]
  7. Rappuoli R., De Gregorio E.. A sweet T cell response. Nature Medicine. 2011;17(12):1551–1552. doi: 10.1038/nm.2587. [DOI] [PubMed] [Google Scholar]
  8. Kay E., Cuccui J., Wren B. W.. Recent advances in the production of recombinant glycoconjugate vaccines. npj Vaccines. 2019;4(1):16. doi: 10.1038/s41541-019-0110-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Terra V. S., Mills D. C., Yates L. E., Abouelhadid S., Cuccui J., Wren B. W.. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J. Med. Microbiol. 2012;61(7):919–926. doi: 10.1099/jmm.0.039438-0. [DOI] [PubMed] [Google Scholar]
  10. Wren B. W., Hall C. L., Terra V. S., Harrison M. A., Atkins E., Nasher F., Passmore I. J.. Recent Advances in Bioconjugate Vaccine Development. Vaccines. 2025;13(7):703. doi: 10.3390/vaccines13070703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Wacker M., Linton D., Hitchen P. G., Nita-Lazar M., Haslam S. M., North S. J., Panico M., Morris H. R., Dell A., Wren B. W., Aebi M.. N-Linked Glycosylation in Campylobacter jejuni and Its Functional Transfer into E. coli. Science. 2002;298(5599):1790–1793. doi: 10.1126/science.298.5599.1790. [DOI] [PubMed] [Google Scholar]
  12. Musumeci M. A., Hug I., Scott N. E., Ielmini M. V., Foster L. J., Wang P. G., Feldman M. F.. In Vitro Activity of Neisseria meningitidis PglL O-Oligosaccharyltransferase with Diverse Synthetic Lipid Donors and a UDP-activated Sugar. J. Biol. Chem. 2013;288(15):10578–10587. doi: 10.1074/jbc.M112.432815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sun P., Pan C., Zeng M., Liu B., Liang H., Wang D., Liu X., Wang B., Lyu Y., Wu J., Zhu L., Wang H.. Design and production of conjugate vaccines against S. Paratyphi A using an O-linked glycosylation system in vivo. npj Vaccines. 2018;3(1):4. doi: 10.1038/s41541-017-0037-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pan C., Wu J., Qing S., Zhang X., Zhang L., Yue H., Zeng M., Wang B., Yuan Z., Qiu Y., Ye H., Wang D., Liu X., Sun P., Liu B., Feng E., Gao X., Zhu L., Wei W., Ma G., Wang H.. Biosynthesis of Self-Assembled Proteinaceous Nanoparticles for Vaccination. Adv. Mater. 2020;32(42):2002940. doi: 10.1002/adma.202002940. [DOI] [PubMed] [Google Scholar]
  15. Li C., Li J., Sun P., Li T., Yan X., Ye J., Wu J., Zhu L., Wang H., Pan C.. Production of Promising Heat-Labile Enterotoxin (LT) B Subunit-Based Self-Assembled Bioconjugate Nanovaccines against Infectious Diseases. Vaccines. 2024;12(4):347. doi: 10.3390/vaccines12040347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Zhang Y., Sun P., Li T., Li J., Ye J., Li X., Wu J., Lu Y., Zhu L., Wang H., Pan C.. Efficient Production of Self-Assembled Bioconjugate Nanovaccines against Klebsiella pneumoniae O2 Serotype in Engineered Escherichia coli. Nanomaterials. 2024;14(8):728. doi: 10.3390/nano14080728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Skurnik M., Biedzka-Sarek M., Lübeck P. S., Blom T., Bengoechea J. A., Pérez-Gutiérrez C., Ahrens P., Hoorfar J.. Characterization and Biological Role of the O-Polysaccharide Gene Cluster ofYersinia enterocoliticaSerotype O:9. J. Bacteriol. 2007;189(20):7244–7253. doi: 10.1128/JB.00605-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Huang J., Pan C., Sun P., Feng E., Wu J., Zhu L., Wang H.. Application of an O-Linked Glycosylation System in Yersinia enterocolitica Serotype O:9 to Generate a New Candidate Vaccine against Brucella abortus. Microorganisms. 2020;8(3):436. doi: 10.3390/microorganisms8030436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Iwashkiw J. A., Fentabil M. A., Faridmoayer A., Mills D. C., Peppler M., Czibener C., Ciocchini A. E., Comerci D. J., Ugalde J. E., Feldman M. F.. Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis. Microb. Cell Fact. 2012;11(1):13. doi: 10.1186/1475-2859-11-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Smith D. M., Simon J. K., Baker J. R. Jr. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 2013;13(8):592–605. doi: 10.1038/nri3488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pan C., Yue H., Zhu L., Ma G.-H., Wang H.-l.. Prophylactic vaccine delivery systems against epidemic infectious diseases. Adv. Drug Delivery Rev. 2021;176:113867. doi: 10.1016/j.addr.2021.113867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Geng Z., Cao Z., Liu J.. Recent advances in targeted antibacterial therapy basing on nanomaterials. Exploration. 2023;3(1):20210117. doi: 10.1002/EXP.20210117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hassebroek A. M., Sooryanarain H., Heffron C. L., Hawks S. A., LeRoith T., Cecere T. E., Stone W. B., Walter D., Mahsoub H. M., Wang B., Tian D., Ivester H. M., Allen I. C., Auguste A. J., Duggal N. K., Zhang C., Meng X. J.. A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection. J. Med. Virol. 2023;95(2):e28503. doi: 10.1002/jmv.28503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pan C., Yu S., Li C., Li J., Sun P., Guo Y., Li T., Wang D., Wang K., Lyu Y., Liu X., Li X., Wu J., Zhu L., Wang H.. Rapid and efficient immune response induced by a designed modular cholera toxin B subunit (CTB)-based self-assembling nanoparticle. Biomaterials. 2025;315:122946. doi: 10.1016/j.biomaterials.2024.122946. [DOI] [PubMed] [Google Scholar]
  25. Liu X., Chang X., Rothen D., Derveni M., Krenger P., Roongta S., Wright E., Vogel M., Tars K., Mohsen M. O., Bachmann M. F.. AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate. Vaccines. 2021;9(4):403. doi: 10.3390/vaccines9040403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yamashita I., Iwahori K., Kumagai S.. Ferritin in the field of nanodevices. Biochim. Biophys. Acta, Gen. Subj. 2010;1800(8):846–857. doi: 10.1016/j.bbagen.2010.03.005. [DOI] [PubMed] [Google Scholar]
  27. Weidenbacher P. A. B., Sanyal M., Friedland N., Tang S., Arunachalam P. S., Hu M., Kumru O. S., Morris M. K., Fontenot J., Shirreff L., Do J., Cheng Y.-C., Vasudevan G., Feinberg M. B., Villinger F. J., Hanson C., Joshi S. B., Volkin D. B., Pulendran B., Kim P. S.. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nat. Commun. 2023;14(1):2149. doi: 10.1038/s41467-023-37417-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Houser K. V., Chen G. L., Carter C., Crank M. C., Nguyen T. A., Burgos Florez M. C., Berkowitz N. M., Mendoza F., Hendel C. S., Gordon I. J., Coates E. E., Vazquez S., Stein J., Case C. L., Lawlor H., Carlton K., Gaudinski M. R., Strom L., Hofstetter A. R., Liang C. J., Narpala S., Hatcher C., Gillespie R. A., Creanga A., Kanekiyo M., Raab J. E., Andrews S. F., Zhang Y., Yang E. S., Wang L., Leung K., Kong W.-P., Freyn A. W., Nachbagauer R., Palese P., Bailer R. T., McDermott A. B., Koup R. A., Gall J. G., Arnold F., Mascola J. R., Graham B. S., Ledgerwood J. E., Casazza J., Holman L., Ola A. O., Costner P., Cunningham J., Larkin B., Novik L., Saunders J., Whalen W., Wang X., Eshun A. M., Taylor A., Cheng K. C., Laurencot C., Cox J. H., Sitar S., Le L., Pittman I., Vasilenko O., Rothwell R. S., Yamshchikov G., Burch E., Hickman S., Trofymenko O., Boyd C., Apte P., Cartagena C. T., Hicks R., Williams P., Blaku Z., Tran C.. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 2022;28(2):383–391. doi: 10.1038/s41591-021-01660-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wang W., Zhou X., Bian Y., Wang S., Chai Q., Guo Z., Wang Z., Zhu P., Peng H., Yan X., Li W., Fu Y.-X., Zhu M.. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat. Nanotechnol. 2020;15(5):406–416. doi: 10.1038/s41565-020-0648-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rodrigues M. Q., Alves P. M., Roldão A.. Functionalizing Ferritin Nanoparticles for Vaccine Development. Pharmaceutics. 2021;13(10):1621. doi: 10.3390/pharmaceutics13101621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pan C., Sun P., Liu B., Liang H., Peng Z., Dong Y., Wang D., Liu X., Wang B., Zeng M., Wu J., Zhu L., Wang H., Cassone A.. Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System. mBio. 2016;7(2):e00443-16. doi: 10.1128/mbio.00443-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Betzler A. C., Ushmorov A., Brunner C.. The transcriptional program during germinal center reaction - a close view at GC B cells, Tfh cells and Tfr cells. Front. Immunol. 2023;14:1125503. doi: 10.3389/fimmu.2023.1125503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Victora G. D., Nussenzweig M. C.. Germinal Centers. Annu. Rev. Immunol. 2022;40(1):413–442. doi: 10.1146/annurev-immunol-120419-022408. [DOI] [PubMed] [Google Scholar]
  34. Bhat A. H., Maity S., Giri K., Ambatipudi K.. Protein glycosylation: Sweet or bitter for bacterial pathogens? Crit. Rev. Microbiol. 2019;45(1):82–102. doi: 10.1080/1040841X.2018.1547681. [DOI] [PubMed] [Google Scholar]
  35. Dow J. M., Mauri M., Scott T. A., Wren B. W.. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production. Expert Rev. Vaccines. 2020;19(6):507–527. doi: 10.1080/14760584.2020.1775077. [DOI] [PubMed] [Google Scholar]
  36. Zygmunt M. S., Blasco J. M., Letesson J.-J., Cloeckaert A., Moriyon I.. DNA polymorphism analysis of Brucella lipopolysaccharide genes reveals marked differences in O-polysaccharide biosynthetic genes between smooth and rough Brucella species and novel species-specific markers. BMC Microbiol. 2009;9(1):92. doi: 10.1186/1471-2180-9-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Gu W., Wang X., Qiu H., Cui B., Zhao S., Zheng H., Xiao Y., Liang J., Duan R., Jing H., McCormick B. A.. Comparison of Cytokine Immune Responses to Brucella abortus and Yersinia enterocolitica Serotype O:9 Infections in BALB/c Mice. Infect. Immun. 2013;81(12):4392–4398. doi: 10.1128/IAI.00856-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Abushahba M. F., Dadelahi A. S., Lemoine E. L., Skyberg J. A., Vyas S., Dhoble S., Ghodake V., Patravale V. B., Adamovicz J. J.. Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice. Vaccines. 2023;11(3):546. doi: 10.3390/vaccines11030546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Liu S., Hu M., Liu X., Liu X., Chen T., Zhu Y., Liang T., Xiao S., Li P., Ma X.. Nanoparticles and Antiviral Vaccines. Vaccines. 2023;12(1):30. doi: 10.3390/vaccines12010030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tsoras A. N., Champion J. A.. Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications. Annu. Rev. Chem. Biomol. Eng. 2019;10(1):337–359. doi: 10.1146/annurev-chembioeng-060718-030347. [DOI] [PubMed] [Google Scholar]
  41. Das A., Ali N.. Nanovaccine: an emerging strategy. Expert Rev. Vaccines. 2021;20(10):1273–1290. doi: 10.1080/14760584.2021.1984890. [DOI] [PubMed] [Google Scholar]
  42. Kheirollahpour M., Mehrabi M., Dounighi N. M., Mohammadi M., Masoudi A.. Nanoparticles and Vaccine Development. Pharm. Nanotechnol. 2020;8(1):6–21. doi: 10.2174/2211738507666191024162042. [DOI] [PubMed] [Google Scholar]
  43. Cimica V., Galarza J. M.. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin. Immunol. 2017;183:99–108. doi: 10.1016/j.clim.2017.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tenchov R., Bird R., Curtze A. E., Zhou Q.. Lipid NanoparticlesFrom Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11):16982–17015. doi: 10.1021/acsnano.1c04996. [DOI] [PubMed] [Google Scholar]
  45. Hald Albertsen C., Kulkarni J. A., Witzigmann D., Lind M., Petersson K., Simonsen J. B.. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv Rev. 2022;188:114416. doi: 10.1016/j.addr.2022.114416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Song N., Zhang J., Zhai J., Hong J., Yuan C., Liang M.. Ferritin: A Multifunctional Nanoplatform for Biological Detection, Imaging Diagnosis, and Drug Delivery. Acc. Chem. Res. 2021;54(17):3313–3325. doi: 10.1021/acs.accounts.1c00267. [DOI] [PubMed] [Google Scholar]
  47. Cao S., Ma D., Ji S., Zhou M., Zhu S.. Self-Assembled Ferritin Nanoparticles for Delivery of Antigens and Development of Vaccines: From Structure and Property to Applications. Molecules. 2024;29(17):4221. doi: 10.3390/molecules29174221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Arunachalam P. S., Walls A. C., Golden N., Atyeo C., Fischinger S., Li C., Aye P., Navarro M. J., Lai L., Edara V. V., Röltgen K., Rogers K., Shirreff L., Ferrell D. E., Wrenn S., Pettie D., Kraft J. C., Miranda M. C., Kepl E., Sydeman C., Brunette N., Murphy M., Fiala B., Carter L., White A. G., Trisal M., Hsieh C.-L., Russell-Lodrigue K., Monjure C., Dufour J., Spencer S., Doyle-Meyers L., Bohm R. P., Maness N. J., Roy C., Plante J. A., Plante K. S., Zhu A., Gorman M. J., Shin S., Shen X., Fontenot J., Gupta S., O’Hagan D. T., Van Der Most R., Rappuoli R., Coffman R. L., Novack D., McLellan J. S., Subramaniam S., Montefiori D., Boyd S. D., Flynn J. L., Alter G., Villinger F., Kleanthous H., Rappaport J., Suthar M. S., King N. P., Veesler D., Pulendran B.. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021;594(7862):253–258. doi: 10.1038/s41586-021-03530-2. [DOI] [PubMed] [Google Scholar]
  49. Wijesundara Y. H., Howlett T. S., Kumari S., Gassensmith J. J.. The Promise and Potential of Metal-Organic Frameworks and Covalent Organic Frameworks in Vaccine Nanotechnology. Chem. Rev. 2024;124(6):3013–3036. doi: 10.1021/acs.chemrev.3c00409. [DOI] [PubMed] [Google Scholar]
  50. Li S., Huang J., Wang K., Liu Y., Guo Y., Li X., Wu J., Sun P., Wang Y., Zhu L., Wang H.. A bioconjugate vaccine against Brucella abortus produced by engineered Escherichia coli. Front. Bioeng. Biotech. 2023;11:1121074. doi: 10.3389/fbioe.2023.1121074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wang S., Zhao X., Sun K., Bateer H., Wang W.. The Genome Sequence of Brucella abortus vaccine strain A19 provides insights on its virulence attenuation compared to Brucella abortus strain 9–941. Gene. 2022;830:146521. doi: 10.1016/j.gene.2022.146521. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

id5c00260_si_001.pdf (856.3KB, pdf)

Articles from ACS Infectious Diseases are provided here courtesy of American Chemical Society

RESOURCES